1
|
Odonne G, Musset L, Cropet C, Philogene B, Gaillet M, Tareau MA, Douine M, Michaud C, Davy D, Epelboin L, Lazrek Y, Brousse P, Travers P, Djossou F, Mosnier E. When local phytotherapies meet biomedicine. Cross-sectional study of knowledge and intercultural practices against malaria in Eastern French Guiana. J Ethnopharmacol 2021; 279:114384. [PMID: 34217796 DOI: 10.1016/j.jep.2021.114384] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Revised: 06/28/2021] [Accepted: 06/29/2021] [Indexed: 06/13/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE In French Guiana, traditional phytotherapies are an important part of self-healthcare, however, a precise understanding of the interactions between local phytotherapies and biomedicine is lacking. Malaria is still endemic in the transition area between French Guiana and Brazil, and practices of self-treatment, although difficult to detect, have possible consequences on the outcome of public health policies. AIM OF THE STUDY The objectives of this research were 1) to document occurences of co-medication (interactions between biomedicine and local phytotherapies) against malaria around Saint-Georges de l'Oyapock (SGO), 2) to quantify and to qualify plant uses against malaria, 3) and to discuss potential effects of such co-medications, in order to improve synergy between community efforts and public health programs in SGO particularly, and in Amazonia more broadly. MATERIALS AND METHODS This cross-sectional study was conducted in 2017 in SGO. Inhabitants of any age and nationality were interviewed using a questionnaire (122 questions) about their knowledge and habits regarding malaria, and their use of plants to prevent and treat it. They were invited to show their potential responses on a poster illustrating the most common antimalarial plants used in the area. In order to correlate plant uses and malaria epidemiology, all participants subsequently received a medical examination, and malaria detection was performed by Rapid Diagnostic Test (RDT) and Polymerase Chain Reaction (PCR). RESULTS A total of 1566 inhabitants were included in the study. Forty-six percent of them declared that they had been infected by malaria at least once, and this rate increased with age. Every person who reported that they had had malaria also indicated that they had taken antimalarial drugs (at least for the last episode), and self-medication against malaria with pharmaceuticals was reported in 142 cases. A total of 550 plant users was recorded (35.1% of the interviewed population). Among them 95.5% associated pharmaceuticals to plants. All plants reported to treat malaria were shared by every cultural group around SGO, but three plants were primarily used by the Palikur: Cymbopogon citratus, Citrus aurantifolia and Siparuna guianensis. Two plants stand out among those used by Creoles: Eryngium foetidum and Quassia amara, although the latter is used by all groups and is by far the most cited plant by every cultural group. Cultivated species accounts for 91.3% of the use reports, while wild taxa account for only 18.4%. CONCLUSIONS This study showed that residents of SGO in French Guiana are relying on both traditional phytotherapies and pharmaceutical drugs to treat malaria. This medical pluralism is to be understood as a form of pragmatism: people are collecting or cultivating plants for medicinal purposes, which is probably more congruent with their respective cultures and highlights the wish for a certain independence of the care process. A better consideration of these practices is thus necessary to improve public health response to malaria.
Collapse
Affiliation(s)
- G Odonne
- UMR 3456 LEEISA (Laboratoire Ecologie, Evolution, Interactions des Systèmes Amazoniens), CNRS, Université de Guyane, IFREMER, Cayenne, French Guiana.
| | - L Musset
- Laboratoire de parasitologie, Centre National de Référence du Paludisme, Pôle Zones Endémiques, WHO Collaborating Center for Surveillance of Antimalarial Drug Resistance, Institut Pasteur de la Guyane, 23 avenue Pasteur, Cayenne, French Guiana
| | - C Cropet
- Centre d'Investigation Clinique Antilles Guyane - Inserm 1424, Centre Hospitalier de Cayenne Andrée Rosemon, rue des flamboyants, Cayenne, French Guiana
| | - B Philogene
- DAAC NGO, Saint Georges de l'Oyapock, French Guiana
| | - M Gaillet
- Pôle santé publique Recherche, Coordination des Centres délocalisés de prévention et de soin, Centre hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - M-A Tareau
- UMR 3456 LEEISA (Laboratoire Ecologie, Evolution, Interactions des Systèmes Amazoniens), CNRS, Université de Guyane, IFREMER, Cayenne, French Guiana
| | - M Douine
- Centre d'Investigation Clinique Antilles Guyane - Inserm 1424, Centre Hospitalier de Cayenne Andrée Rosemon, rue des flamboyants, Cayenne, French Guiana; TBIP, U1019-UMR9017-CIIL (Centre d'Infection et d'Immunité de Lille), Université de Guyane, Université de Lille, CNRS, Inserm, Institut Pasteur de Lille, Cayenne, French Guiana
| | - C Michaud
- Pôle santé publique Recherche, Coordination des Centres délocalisés de prévention et de soin, Centre hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - D Davy
- UMR 3456 LEEISA (Laboratoire Ecologie, Evolution, Interactions des Systèmes Amazoniens), CNRS, Université de Guyane, IFREMER, Cayenne, French Guiana
| | - L Epelboin
- Centre d'Investigation Clinique Antilles Guyane - Inserm 1424, Centre Hospitalier de Cayenne Andrée Rosemon, rue des flamboyants, Cayenne, French Guiana; Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Y Lazrek
- Laboratoire de parasitologie, Centre National de Référence du Paludisme, Pôle Zones Endémiques, WHO Collaborating Center for Surveillance of Antimalarial Drug Resistance, Institut Pasteur de la Guyane, 23 avenue Pasteur, Cayenne, French Guiana
| | - P Brousse
- Pôle santé publique Recherche, Coordination des Centres délocalisés de prévention et de soin, Centre hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - P Travers
- Pôle santé publique Recherche, Coordination des Centres délocalisés de prévention et de soin, Centre hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - F Djossou
- Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - E Mosnier
- Unité de Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana; SESSTIM (Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale), Aix Marseille University, INSERM, IRD, Marseille, France
| |
Collapse
|
2
|
Mosnier E, Djossou F, Priam R, Demar M, Epelboin L, Carbunar A, Douine M, Gaillet M, Lazrek Y, Musset L. Stratégie de dépistage du paludisme par PCR et traitement ciblé en population générale, en zone de transmission, en Guyane. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
Mosnier E, Djossou F, Priam R, Carbunar A, Demar M, Landier J, Roux E, Gaudart J, Lazrek Y, Musset L. Profil épidémiologique des infections à Plasmodium vivax dans une région endémique en Guyane, étude de cohorte, 2007–2018. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Boleto G, Comarmond C, Ghillani-Dalbin P, Musset L, Biard L, Mulier G, Saadoun D, Cacoub P. Cryoglobulinémie mixte après l’ère de l’infection par le virus l’hépatite C. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Neil J, Choumet V, Beadon K, Delmont E, Ghillani P, Boucraut J, Musset L, Léger JM. Native versus deglycosylated IgM in anti-MAG neuropathy: Correlation with clinical status - Study of 10 cases. J Neuroimmunol 2019; 339:577094. [PMID: 31756640 DOI: 10.1016/j.jneuroim.2019.577094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 10/30/2019] [Accepted: 10/30/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND/PURPOSE In anti-myelin associated glycoprotein (anti-MAG) neuropathies, there is evidence that anti-MAG antibodies are pathogenic but numerous studies report the absence or a weak correlation between the titers of these antibodies and disease course. In this study we assessed the relationships between MAG and glycosylated moieties located on Fc fragment of IgM anti-MAG. MATERIAL AND METHODS IgM were extracted from the serum of 8 patients with anti-MAG neuropathy and in 2 patients with anti-MAG antibodies without anti-MAG neuropathy. Anti-MAG activity was performed with pre- and post-deglycosylated IgM extracts using indirect immunofluorescence (IIF) and ELISA. Sera from 49 patients with IgM monoclonal gammopathy without neurological disease were tested as control group (CG). Results were compared to clinical scores. For 4 patients the affinity constant of IgM with MAG was analyzed pre- and post-deglycosylated, using surface plasmon resonance technology (SPR). RESULTS The relationships between MAG and glycosylated moieties of IgM anti-MAG were confirmed by kinetic and immunological assays. Deglycosylation resulted in a decrease in anti-MAG titers. Post-deglycosylation anti-MAG titers trended with changes in IgM titers and allowed quantifying anti-MAG antibodies without a saturation of the testing method. After deglycosylation, the titers better represented pathogenic activity and help to follow a given patient's clinical status prospectively. Six patients from CG (12.2%) had anti-MAG antibody titers over positive threshold: 1000 Bühlmann-Titer-Units (BTU) supporting the hypothesis of neutral intermolecular interactions between IgM and MAG. Deglycosylation allowed distinguishing infra clinical forms from neutral relationships forms, when the titers are weak but this assay remains essentially a diagnostic tool.
Collapse
Affiliation(s)
- J Neil
- Department of Immunology, UF of Autoimmunity, Hospital Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, France.
| | - V Choumet
- Unit Environment and Infectious Risks, Pasteur Institute, Paris, France
| | - K Beadon
- Referral Center for Neuromuscular Disorders, Hôpital Pitié Salpêtrière et Université Paris VI, Paris, France
| | - E Delmont
- France Referral Center for Neuromuscular Disorders and ALS, La Timone Hospital, Aix-Marseille University, France
| | - P Ghillani
- Department of Immunology, UF of Autoimmunity, Hospital Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, France
| | - J Boucraut
- University Hospital la Conception, Marseille, 5, France
| | - L Musset
- Department of Immunology, UF of Autoimmunity, Hospital Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, France
| | - J M Léger
- Referral Center for Neuromuscular Disorders, Hôpital Pitié Salpêtrière et Université Paris VI, Paris, France
| |
Collapse
|
6
|
Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Bolko L, Maisonobe T, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathol Appl Neurobiol 2019; 45:513-522. [PMID: 30267437 DOI: 10.1111/nan.12519] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 09/17/2018] [Indexed: 12/31/2022]
Abstract
AIMS To elucidate the diagnostic value of sarcoplasmic expression of myxovirus resistance protein A (MxA) for dermatomyositis (DM) specifically analysing different DM subforms, and to test the superiority of MxA to other markers. METHODS Immunohistochemistry for MxA and retinoic acid-inducible gene I (RIG-I) was performed on skeletal muscle samples and compared with the item presence of perifascicular atrophy (PFA) in 57 DM patients with anti-Mi-2 (n = 6), -transcription intermediary factor 1 gamma (n = 10), -nuclear matrix protein 2 (n = 13), -melanoma differentiation-associated gene 5 (MDA5) (n = 10) or -small ubiquitin-like modifier activating enzyme (n = 1) autoantibodies and with no detectable autoantibody (n = 17). Among the patients, nine suffered from cancer and 22 were juvenile-onset type. Disease controls included antisynthetase syndrome (ASS)-associated myositis (n = 30), immune-mediated necrotizing myopathy (n = 9) and inclusion body myositis (n = 5). RESULTS Sarcoplasmic MxA expression featured 77% sensitivity and 100% specificity for overall DM patients, while RIG-I staining and PFA reached respectively 14% and 59% sensitivity and 100% and 86% specificity. In any subset of DM, sarcoplasmic MxA expression showed higher sensitivity than RIG-I and PFA. Some anti-MDA5 antibody-positive DM samples distinctively showed a scattered staining pattern of MxA. No ASS samples had sarcoplasmic MxA expression even though six patients had DM skin rash. CONCLUSIONS Sarcoplasmic MxA expression is more sensitive than PFA and RIG-I expression for a pathological diagnosis of DM, regardless of the autoantibody-related subgroup. In light of its high sensitivity and specificity, it may be considered a pathological hallmark of DM per se. Also, lack of MxA expression in ASS supports the idea that ASS is a distinct entity from DM.
Collapse
Affiliation(s)
- A Uruha
- Mixed Research Unit (UMR) 974, Center of Research in Myology, Institute of Myology, Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
| | - Y Allenbach
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| | - J-L Charuel
- Immunochemistry & Autoimmunity Laboratory, Department of Immunology, APHP, Pitié-Salpêtrière University Hospital, Paris, France
| | - L Musset
- Immunochemistry & Autoimmunity Laboratory, Department of Immunology, APHP, Pitié-Salpêtrière University Hospital, Paris, France
| | - A Aussy
- Department of Immunology, Rouen University Hospital, INSERM, Rouen Normandie University, Rouen, France
| | - O Boyer
- Department of Immunology, Rouen University Hospital, INSERM, Rouen Normandie University, Rouen, France
| | - K Mariampillai
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| | - O Landon-Cardinal
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| | - C Rasmussen
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| | - L Bolko
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| | - T Maisonobe
- Reference Center for Neuromuscular Pathologies, Institute of Myology, APHP, Pitié-Salpêtrière University Hospital, Paris, France
| | - S Leonard-Louis
- Reference Center for Neuromuscular Pathologies, Institute of Myology, APHP, Pitié-Salpêtrière University Hospital, Paris, France
| | - S Suzuki
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - I Nishino
- Department of Neuromuscular Research, National Institute of Neuroscience, Tokyo, Japan
- Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - W Stenzel
- Department of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany
| | - O Benveniste
- UMR974, Department of Internal Medicine and Clinical Immunology, Public Assistance-Hospitals of Paris (APHP), Pitié-Salpêtrière University Hospital, National Institute of Health and Medical Research (INSERM), Paris-Sorbonne University, Paris, France
- Inflammation-Immunopathology-Biotherapy Department (DHU I2B), and Reference Center for Neuromuscular Pathologies, Institute of Myology, Paris, France
| |
Collapse
|
7
|
Thellier M, Simard F, Musset L, Cot M, Velut G, Kendjo E, Pradines B. Changes in malaria epidemiology in France and worldwide, 2000-2015. Med Mal Infect 2019; 50:99-112. [PMID: 31257063 DOI: 10.1016/j.medmal.2019.06.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 06/11/2019] [Indexed: 12/15/2022]
Abstract
In 2015, 212 million new cases of malaria were reported, causing 429,000 deaths. The World Health Organization (WHO) estimated a 41% decrease in the number of new cases worldwide between 2000 and 2015. The number of deaths from malaria fell by 62% worldwide and by 71% in Africa. In mainland France, malaria is mainly imported by travelers or migrants from endemic areas, in particular sub-Saharan Africa (95%). In France, the number of imported malaria cases, mainly due to Plasmodium falciparum (85%), was estimated at about 82,000 for the period 2000-2015. Over the same period, 6,468 cases of malaria were reported in the French armed forces, of which 2,430 cases (37.6%) were considered as imported because occurring outside of endemic areas. The number of malaria cases also fell between 2000 and 2015 in Mayotte and French Guiana, a malaria transmission zone. Mayotte has entered the elimination of malaria with less than 15 cases per year. In French Guiana, between 300 and 500 cases have been reported annually in recent years. The decline in morbidity and mortality is usually attributed to vector control measures and improved access to effective treatments. However, the Anopheles mosquitoes that transmit the disease have developed resistance against most insecticides. Similarly, malaria parasites have developed resistance against most of the antimalarial drugs used as prevention or treatment, even the latest marketed combinations such as artemisinin-based combination therapies.
Collapse
Affiliation(s)
- M Thellier
- Service de parasitologie-mycologie, Centre national de référence du paludisme, hôpital Pitié-Salpêtrière, Assistance publique Hôpitaux de Paris, 47, boulevard de l'Hôpital, 75013 Paris, France; UMRS 1136, iPLESP, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 27, rue Chaligny, 75571 Paris 12, France; UPMC, faculté de médecine, Sorbonne université, université Pierre-et-Marie-Curie, 91, boulevard de l'Hôpital, 75013 Paris, France
| | - F Simard
- MIVEGEC, IRD-CNRS-university Montpellier, 911, avenue Agropolis, BP 64501, 34394 Montpellier, France
| | - L Musset
- Laboratoire de parasitologie, Centre collaborateur OMS pour la surveillance des résistances aux antipaludiques, institut Pasteur de la Guyane, 23, avenue Louis Pasteur, 97300 Cayenne, France; Centre national de référence du paludisme, institut Pasteur de la Guyane, 23, avenue Louis Pasteur, 97300 Cayenne, France
| | - M Cot
- UMR2016, unité Mère et enfant face aux infections tropicales, institut de recherche pour le développement, 4, avenue de l'Observatoire, 75006 Paris, France
| | - G Velut
- Centre d'épidémiologie et de santé publique des armées, GSBdD Marseille Aubagne, BP 40026, 13568 Marseille cedex 02, France; Direction interarmées du service de santé des armées, Quartier La Madeleine, 97306 Cayenne, France
| | - E Kendjo
- Service de parasitologie-mycologie, Centre national de référence du paludisme, hôpital Pitié-Salpêtrière, Assistance publique Hôpitaux de Paris, 47, boulevard de l'Hôpital, 75013 Paris, France; UMRS 1136, iPLESP, institut Pierre-Louis d'épidémiologie et de santé publique, Sorbonne université, 27, rue Chaligny, 75571 Paris 12, France; UPMC, faculté de médecine, Sorbonne université, université Pierre-et-Marie-Curie, 91, boulevard de l'Hôpital, 75013 Paris, France
| | - B Pradines
- Unité parasitologie et entomologie, institut de recherche biomédicale des armées, institut hospitalo-universitaire Méditerranée Infection, 19-21, boulevard Jean-Moulin, 13005 Marseille, France; Aix Marseille université, IRD, AP-HM, SSA, VITROME, institut hospitalo-universitaire Méditerranée Infection, 19-21, boulevard Jean-Moulin, 13005 Marseille, France; Institut hospitalo-universitaire Méditerranée Infection, 19-21, boulevard Jean-Moulin, 13005 Marseille, France; Centre national de référence du paludisme, institut hospitalo-universitaire Méditerranée Infection, 19-21, boulevard Jean-Moulin, 13005 Marseille, France.
| |
Collapse
|
8
|
Gaillet M, Musset L, Cropet C, Mallard A, moriceau O, Djossou F, Michaud C, Nacher M, Mosnier E. Identifier les groupes sociaux à faible niveau de connaissance du paludisme afin de mieux cibler les programmes d’éducation dans un contexte amazonien, multiculturel et transfrontalier. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Mosnier E, Dusfour I, Lacour G, Restrepo J, Sanna A, Musset L, Michaud C, Ardillon V, Djossou F, Roux E. Foyer épidémique de paludisme autochtone à P. vivax en Guyane à la frontière avec le Brésil, 2017. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Mosnier E, Roux E, Cropet C, Lazrek Y, Gaillet M, Mathieu L, Moriceau O, Pelleau S, Djossou F, Musset L. Répartition spatiale et facteurs de risque de portage de paludisme à la frontière entre la Guyane et le Brésil. Med Mal Infect 2019. [DOI: 10.1016/j.medmal.2019.04.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Damoiseaux J, Vulsteke JB, Tseng CW, Platteel AC, Piette Y, Shovman O, Bonroy C, Hamann D, De Langhe E, Musset L, Chen YH, Shoenfeld Y, Allenbach Y, Bossuyt X. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 2019; 18:293-305. [DOI: 10.1016/j.autrev.2018.10.004] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Accepted: 10/23/2018] [Indexed: 12/13/2022]
|
12
|
Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, Bughin V, Jouen F, Musset L, Allenbach Y, Hachulla E, Maillard H, Meyer A, Bourrat E, Benveniste O. French expert opinion for the management of juvenile dermatomyositis. Arch Pediatr 2019; 26:120-125. [DOI: 10.1016/j.arcped.2018.12.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 07/17/2018] [Accepted: 12/02/2018] [Indexed: 12/24/2022]
|
13
|
Douine M, Lazrek Y, Blanchet D, Pelleau S, Chanlin R, Corlin F, Hureau L, Volney B, Hiwat H, Vreden S, Djossou F, Demar M, Nacher M, Musset L. Predictors of antimalarial self-medication in illegal gold miners in French Guiana: a pathway towards artemisinin resistance. J Antimicrob Chemother 2018; 73:231-239. [PMID: 29045645 DOI: 10.1093/jac/dkx343] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 08/23/2017] [Indexed: 11/15/2022] Open
Abstract
Background Malaria is endemic in French Guiana (FG), South America. Despite the decrease in cases in the local population, illegal gold miners are very affected by malaria (22.3% of them carried Plasmodium spp.). Self-medication seems to be very common, but its modalities and associated factors have not been studied. The aim of this study was to evaluate parasite susceptibility to drugs and to document behaviours that could contribute to resistance selection in illegal gold miners. Methods This multicentric cross-sectional study was conducted in resting sites along the FG-Surinamese border. Participating gold miners working in FG completed a questionnaire and provided a blood sample. Results From January to June 2015, 421 illegal gold miners were included. Most were Brazilian (93.8%) and 70.5% were male. During the most recent malaria attack, 45.5% reported having been tested for malaria and 52.4% self-medicated, mainly with artemisinin derivatives (90%). Being in FG during the last malaria attack was the main factor associated with self-medication (adjusted OR = 22.1). This suggests that access to malaria diagnosis in FG is particularly difficult for Brazilian illegal gold miners. Treatment adherence was better for persons who reported being tested. None of the 32 samples with Plasmodium falciparum presented any mutation on the pfK13 gene, but one isolate showed a resistance profile to artemisinin derivatives in vitro. Conclusions The risk factors for the selection of resistance are well known and this study showed that they are present in FG with persons who self-medicated with poor adherence. Interventions should be implemented among this specific population to avoid the emergence of artemisinin resistance.
Collapse
Affiliation(s)
- M Douine
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, French Guiana.,Epidemiology of Tropical Parasitoses, EA 3593, Université de Guyane, Cayenne, French Guiana
| | - Y Lazrek
- Laboratoire de Parasitologie, WHO Collaborating Center for Surveillance of Anti-Malarial Drug Resistance, Centre National de Référence du Paludisme, Institut Pasteur de la Guyane, Cayenne, French Guiana
| | - D Blanchet
- Academic Laboratory of Parasitology - Mycology, Cayenne Hospital, Cayenne, French Guiana
| | - S Pelleau
- Laboratoire de Parasitologie, WHO Collaborating Center for Surveillance of Anti-Malarial Drug Resistance, Centre National de Référence du Paludisme, Institut Pasteur de la Guyane, Cayenne, French Guiana
| | - R Chanlin
- Academic Laboratory of Parasitology - Mycology, Cayenne Hospital, Cayenne, French Guiana
| | - F Corlin
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, French Guiana
| | - L Hureau
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, French Guiana
| | - B Volney
- Laboratoire de Parasitologie, WHO Collaborating Center for Surveillance of Anti-Malarial Drug Resistance, Centre National de Référence du Paludisme, Institut Pasteur de la Guyane, Cayenne, French Guiana
| | - H Hiwat
- Ministry of Health, Malaria Program, Paramaribo, Suriname
| | - S Vreden
- Foundation for Scientific Research Suriname (SWOS), Paramaribo, Suriname
| | - F Djossou
- Epidemiology of Tropical Parasitoses, EA 3593, Université de Guyane, Cayenne, French Guiana.,Infectious and Tropical Diseases Department, Cayenne Hospital, Cayenne, French Guiana
| | - M Demar
- Epidemiology of Tropical Parasitoses, EA 3593, Université de Guyane, Cayenne, French Guiana.,Academic Laboratory of Parasitology - Mycology, Cayenne Hospital, Cayenne, French Guiana
| | - M Nacher
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital, French Guiana.,Epidemiology of Tropical Parasitoses, EA 3593, Université de Guyane, Cayenne, French Guiana
| | - L Musset
- Laboratoire de Parasitologie, WHO Collaborating Center for Surveillance of Anti-Malarial Drug Resistance, Centre National de Référence du Paludisme, Institut Pasteur de la Guyane, Cayenne, French Guiana
| |
Collapse
|
14
|
Moriceau O, Musset L, Barbosa R, Larzek Y, Michaud C, Abboud P, Walter G, Cebe M, Djossou F, Mosnier E. Nouvelles stratégies de dépistage de terrain du paludisme : importance et rôle de l’infirmier coordinateur sur le projet PALUSTOP. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Uruha A, Allenbach Y, Maisonobe T, Léonard-Louis S, Charuel J, Musset L, Aussy A, Boyer O, Suzuki S, Nishino I, Stenzel W, Benveniste O. Myxovirus resistance A : un marqueur histologique diagnostique pour la dermatomyosite. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Chiron A, Mathian A, Charuel J, Sterlin D, Ghillani-Dalbin P, Haroche J, Gorochov G, Musset L, Amoura Z, Miyara M. Lupus systémique avec anticorps anti-DFS70. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Uruha A, Allenbach Y, Charuel J, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O. Type 1 interferon signature as a diagnostic marker of dermatomyositis. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Mariampillai K, Granger B, Guiguet M, Amelin D, Charuel J, Musset L, Allenbach Y, Benveniste O. Clinical epidemiology and multidimensional analysis of idiopathic inflammatory myopathies: to a classification based on myositis specific autoantibodies. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Uruha A, Allenbach Y, Charuel J, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O. Type 1 interferon signature as a diagnostic marker of dermatomyositis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Mauhin W, Mariampillai K, Allenbach Y, Musset L, Charuel J, Benveniste O. Anti-mitochondrial antibodies are not a hallmark for severity in inflammatory myopathies. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Musset L, Heugas C, Naldjinan R, Blanchet D, Houze P, Abboud P, Ringwald P, Legrand E, Demar M, Djossou F. Efficacité thérapeutique de la chloroquine dans le traitement des accès palustres simples à Plasmodium vivax en Guyane. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Morer L, Miyara M, Bondeelle L, Uzunhan Y, Ghillani-Dalbin P, Valeyre D, Musset L, Nunes H. Valeur pronostique du taux sérique de KL-6 dans les pneumopathies interstitielles diffuses fibrosantes dans une cohorte française. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Ghillani-Dalbin P, Amoura Z, Cacoub P, Charuel JL, Diemert MC, Piette JC, Musset L. Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. Lupus 2016; 12:833-7. [PMID: 14667099 DOI: 10.1191/0961203303lu475oa] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective was to report our experience of the detection of anti-nucleosome (anti-Nuc) antibodies (Ab) in a large series of consecutive patients, and to compare these results with those of anti-nuclear and anti-dsDNA Ab. In total, 1696 consecutive patients with suspected or confirmed autoimmune disease were tested over a two-year period. The biological investigation included detection of anti-nuclear, anti-dsDNA and anti-Nuc Ab. Among 1696 sera, 382 (23%) were negative for all Ab tested (anti-nuclear, anti-dsDNA and anti-Nuc) and 1314 (77%) were positive for at least one Ab. Anti-Nuc Ab were positive in 350/1314 patients. In this group, 249/350 (71%) also had positive anti-nuclear and anti-dsDNA, 97/350 (28%) had only positive anti-nuclear Ab without anti-dsDNA Ab and 4/350 (1%) had both anti-dsDNA and anti-Nuc Ab without anti-nuclear Ab. No patient had ‘isolated’ anti-Nuc Ab. Clinical data were available for 307/350 anti-Nuc positive patients. Systemic lupus erythematosus (SLE) was diagnosed in 240/307 (78%) patients, including 43 SLE patients with negative anti-dsDNA Ab. In conclusion, this study extends the relevance of anti-Nuc Ab to routine use for the diagnosis of connective tissue diseases, mainly anti-dsDNA Ab negative SLE.
Collapse
|
24
|
Lhote R, Cohen Aubart F, Grenier P, Miyara M, Haroche J, Mathian A, Hie M, Boutin D, Musset L, Amoura Z. Atteintes pulmonaires associées à l’anticorps anti-RNP : étude de 190 patients. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Mosnier E, Djossou F, Pelleau S, Douine M, Guarmit B, Brousse P, Mutricy R, Simonnet C, Gauduchon S, Musset L. TROP-15 - Importance du portage asymptomatique de plasmodies dans un quartier à transmission autochtone du paludisme en Guyane : enjeux pour une stratégie d’élimination. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30523-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Marlet J, Ankri A, Charuel J, Ghillani-Dalbin P, Perret A, Martin-Toutain I, Haroche J, Amoura Z, Musset L, Miyara M. Anticorps anti-DFS70 et thrombophilie. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Gitiaux C, De Antonio M, Aouizerate J, Gherardi R, Guilbert T, Barnerias C, Bodemer C, Brochard-Payet K, Quartier P, Musset L, Chazaud B, Desguerre I, Bader-Meunier B. Vasculopathy as a major marker of severity in juvenile dermatomyositis. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Gallay L, Mariampillai K, Charuel J, Hervier B, Herson S, Musset L, Benveniste O. Marqueurs immunologiques sériques dans une cohorte de 89 patients atteints de myosite à inclusions. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Aussy A, Drouot L, Benveniste O, Musset L, Charuel J, Jouen F, Marie I, Boyer O. Mise au point d’un test de dosage et caractérisation des anticorps anti-TIF1gamma au cours des dermatomyosites paranéoplasiques. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Mauhin W, Schoindre Y, Stojkovic T, Champtiaux N, Mariampillai K, Rigolet A, Miyara M, Charuel J, Herson S, Musset L, Benveniste O. Anticorps anti-mitochondrie et myopathies inflammatoires. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Keraen J, Champtiaux N, Schoindre Y, Mariampillai K, Rigolet A, Musset L, Herson S, Allenbachyves Y, Hervier B, Benveniste O. Possible sur-risque de survenue de cancers synchrones au cours des myosites nécrosantes auto-immunes à anti-HMGCR. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Jouenne R, Chader D, Cohen Aubart F, Haroche J, Mathian A, Musset L, Gorochov G, Amoura Z, Miyara M. Réponse des lymphocytes T régulateurs à des hautes doses de méthylprednisolone au cours du lupus systémique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Jolly M, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Boutin D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Jallouli M, Leroux G, Cohen-Bittan J, Tanguy ML, Hulot JS, Musset L, Amoura Z, Piette JC, Costedoat-Chalumeau N. FRI0434 Blood Hydroxychloroquine (HCQ) Levels do not PREDICT Quality of Life in Systemic Lupus Erythematosus (SLE). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LEC, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EKL, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2013; 73:17-23. [PMID: 24126457 DOI: 10.1136/annrheumdis-2013-203863] [Citation(s) in RCA: 371] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 (p<0.03). Here, we formulated recommendations for the assessment and interpretation of ANA and associated antibodies. Notably, the roles of IIFA as a reference method, and the importance of defining nuclear and cytoplasmic staining, were emphasised, while the need to incorporate alternative automated methods was acknowledged. Various approaches to overcome discrepancies between methods were suggested of which an improved bench-to-bedside communication is of the utmost importance. These recommendations are based on current knowledge and can enable harmonisation of local algorithms for testing and evaluation of ANA and related autoantibodies. Last but not least, new more appropriate terminologies have been suggested.
Collapse
Affiliation(s)
- Nancy Agmon-Levin
- The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, , Tel Aviv, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Allenbach Y, Rigolet A, Drouot L, Charuel J, Jouen F, Jouen F, Maisonobe T, Dubourg O, Behin A, Eymard B, Laforet P, Stojkovic T, Konepaut I, Konepaut I, Cacoub P, Kieffer P, Fain O, Cosserat J, Morati L, Salort E, Menard D, Antoine J, Tournadre A, Menier VB, Ferrer X, Laroche C, Musset L, Herson S, Boyer O, Benveniste O. P.14.11 Auto-immune necrotizing myopathies with anti-HMGCR antibodies are related to statin-exposure only for a minority of cases. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Bloch Queyrat C, Rigolet A, Allenbach Y, Musset L, Treluyer J, Urien S, Benveniste O. P.14.8 Ethnic origins influence the natural history modelling of necrotizing myopathy with anti-SRP antibodies. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Allenbach Y, Leroux G, Uzuhnan Y, Valeyre D, Saadoun D, Aubart F, Hervier B, Hie M, Wipff J, Myiara M, Charuel J, Musset L, Audia S, Devillier H, Bonnote B, Barete S, Nimal N, Rigolet A, Herson S, Benveniste O. P.14.2 Dermatomyositis associated with MDA-5 antibodies: Report of the first European series. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Ayrignac X, Viala K, Koutlidis RM, Taïeb G, Stojkovic T, Musset L, Léger JM, Fournier E, Maisonobe T, Bouche P. Sensory chronic inflammatory demyelinating polyneuropathy: An under-recognized entity? Muscle Nerve 2013; 48:727-32. [DOI: 10.1002/mus.23821] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/12/2013] [Indexed: 11/08/2022]
Affiliation(s)
- Xavier Ayrignac
- Service de Neurologie; CHU Montpellier; Hôpital Gui de Chauliac 34295 Montpellier France
| | - Karine Viala
- Département de Neurophysiologie Clinique; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| | | | - Guillaume Taïeb
- Service de Neurologie CHU Nîmes; Hôpital Carémeau; Nîmes France
| | - Tanya Stojkovic
- Centre de Référence de Pathologie Neuromusculaire Paris Est; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| | - Lucille Musset
- Laboratoire d'immunochimie; Groupe Hospitalier Pitié-Salpêtrière, and Université Paris VI; Paris France
| | - Jean-Marc Léger
- Centre de Référence de Pathologie Neuromusculaire Paris Est; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| | - Emmanuel Fournier
- Département de Neurophysiologie Clinique; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| | - Thierry Maisonobe
- Département de Neurophysiologie Clinique; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| | - Pierre Bouche
- Département de Neurophysiologie Clinique; Groupe Hospitalier Pitié-Salpêtrière; Paris France
| |
Collapse
|
39
|
Pham F, Charuel JL, Ghillani-Dalbin P, Hervier B, Allenbach Y, Nunes H, Valeyre D, Amoura Z, Benveniste O, Musset L, Miyara M. L’absence de fluorescence cytoplasmique dans les cellules HEp-2 est rare en présence d’anticorps anti-synthétase ou d’anti-SRP au cours des myopathies inflammatoires et des pneumopathies interstitielles. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I, Joly F, Rosenzwajg M, Sene D, Benech P, Musset L, Klatzmann D, Meffre E, Cacoub P. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. ACTA ACUST UNITED AC 2013; 65:1085-96. [PMID: 23279883 DOI: 10.1002/art.37828] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Accepted: 12/07/2012] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Primary Sjögren's syndrome (SS) is an autoimmune disease associated with a high risk of developing non-Hodgkin's lymphoma. This study was undertaken to determine the nature of B cells driving lymphoproliferation in primary SS. METHODS B cell subsets and function were analyzed in peripheral blood from 66 adult patients with primary SS (including 14 patients with B cell lymphoproliferative disease [LPD]) and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis. The reactivity of recombinant antibodies isolated from single B cells from patients with primary SS and LPD was tested using an enzyme-linked immunosorbent assay. RESULTS We observed an expansion of an unusual CD21-/low B cell population that correlated with lymphoproliferation in patients with primary SS. A majority of CD21-/low B cells from patients with primary SS expressed autoreactive antibodies, which recognized nuclear and cytoplasmic structures. These B cells belonged to the memory compartment, since their Ig genes were mutated. They were unable to induce calcium flux, become activated, or proliferate in response to B cell receptor and/or CD40 triggering, suggesting that these autoreactive B cells may be anergic. However, CD21-/low B cells from patients with primary SS remained responsive to Toll-like receptor (TLR) stimulation. Molecules specifically expressed in CD21-/low B cells that are likely to induce their unresponsive stage were detected in gene array analyses. CONCLUSION Patients with primary SS who display high frequencies of autoreactive and unresponsive CD21-/low B cells are susceptible to developing lymphoproliferation. These cells remain in peripheral blood controlled by functional anergy instead of being eliminated, and chronic antigenic stimulation through TLR stimulation may create a favorable environment for breaking tolerance and activating these cells.
Collapse
Affiliation(s)
- D Saadoun
- CNRS UMR 7211, INSERM U959, Groupe Hospitalier Pitié-Salpêtrière, and Université Pierre et Marie Curie, Paris 6, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2013; 73:831-7. [PMID: 23606708 PMCID: PMC3995244 DOI: 10.1136/annrheumdis-2012-202770] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Background The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30–40% of patients are non-responders or relapsers to such combination. Objective To analyse the safety and efficacy of Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC vasculitis. Patients and methods Open-label, prospective, cohort study including 23 patients with HCV-MC vasculitis. Peg-IFNα/ribavirin was associated to telaprevir (375 mg three times daily, for 12 weeks, (n=15)) or boceprevir (800 mg three times daily, for 44 weeks, (n=8)) for 48 weeks. Results The median age was 59 (52.5–66) years, with 48.8% women. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. The virological response (ie, HCV RNA negativation) was of 69.6% at week 24 (p=0.005). The cryoglobulin level decreased from 0.44 to 0.06 g/l (p=0.0006) and the C4 level increased from 0.09 to 0.15 g/l (p=0.045). Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received erythropoietin, 9 (39.1%) had red cell transfusion, and 2 (8.7%) had granulocyte stimulating agents. Antiviral therapy discontinuation was required in 8 (34.7%) patients for virological non-response (n=5), virological relapse (n=2) and depression (n=1). Conclusions Peg-IFNα/ribavirin/protease inhibitor combination seems highly effective in HCV-MC. Such therapeutic regimen should be administered cautiously considering the high rate of side effects.
Collapse
Affiliation(s)
- David Saadoun
- Department of Internal Medicine, Service de Médecine Interne, AP-HP, Groupe Hospitalier Pitié-Salpétrière, , Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DBLT, Wechsler B, Hervier B, Miyara M, Morel N, Le Corre N, Arnaud L, Piette JC, Musset L, Autran B, Rozenberg F, Amoura Z. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. ACTA ACUST UNITED AC 2013; 63:3502-11. [PMID: 21811996 DOI: 10.1002/art.30576] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To assess the factors influencing the efficacy of 2 injections of a pandemic 2009 influenza A (H1N1) vaccine in patients with systemic lupus erythematosus (SLE). METHODS We conducted a single-center, observational prospective study of 111 patients who were vaccinated with a monovalent, inactivated, nonadjuvanted, split-virus vaccine during December 2009 and January 2010 and received a second dose of vaccine 3 weeks later. The antibody response was evaluated using the hemagglutination inhibition assay according to the guidelines recommended for the pandemic vaccine, consisting of 3 immunogenicity criteria (i.e., a seroprotection rate of 70%, a seroconversion rate of 40%, and a geometric mean ratio [GMR] of 2.5). RESULTS The 3 immunogenicity criteria were met on day 42 (seroprotection rate 80.0% [95% confidence interval (95% CI) 72.5-87.5%], seroconversion rate 71.8% [95% CI 63.4-80.2%], and GMR 10.3 [95% CI 2.9-14.2]), while only 2 criteria were met on day 21 (seroprotection rate 66.7% [95% CI 57.9-75.4%], seroconversion rate 60.4% [95% CI 51.3-69.5%], and GMR 8.5 [95% CI 3.2-12.0]). The vaccine was well tolerated. Disease activity, assessed by the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index, the British Isles Lupus Assessment Group score, and the Systemic Lupus Activity Questionnaire, did not increase. In the multivariate analysis, vaccination failure was significantly associated with immunosuppressive treatment or a lymphocyte count of ≤ 1.0 × 10⁹/liter. The second injection significantly increased the immunogenicity in these subgroups, but not high enough to fulfill the seroprotection criterion in patients receiving immunosuppressive treatment. CONCLUSION Our findings indicate that the efficacy of the vaccine was impaired in patients who were receiving immunosuppressive drugs or who had lymphopenia. A second injection increased vaccine immunogenicity without reaching all efficacy criteria for a pandemic vaccine in patients receiving an immunosuppressive agent. These results open possibilities for improving anti-influenza vaccination in SLE.
Collapse
Affiliation(s)
- A Mathian
- Centre de Référence National pour les Lupus et le Syndrome des Antiphospholipides, Groupement Hospitalier Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Université Paris 06, and INSERM UMR-S 945, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Drouot L, Charuel JL, Jouen F, Allenbach Y, Miyara M, Musset L, Benveniste O, Boyer O. Nouvelle approche diagnostique pour la détection et le dosage des autoanticorps anti-HMGCoA réductase dans les myopathies nécrosantes. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Allenbach Y, Rigolet A, Guiguet M, Marie I, Hachulla E, Mariampillai K, Jacquot S, Jouen F, Boyer O, Musset L, Herson S, Benveniste O. Efficacité du rituximab pour le des myopathies inflammatoires réfractaires associées aux anticorps anti-histidyl-tRNA synthétases (Étude FORCE-Jo1). Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Ghillani P, Dufat L, Himeur S, Miyara M, Amoura Z, Musset L. Routine use of Zenit RA, a novel chemiluminescent immunoanalyzer in autoimmune disease diagnosis. Auto Immun Highlights 2012; 3:27-31. [PMID: 26000125 PMCID: PMC4389018 DOI: 10.1007/s13317-012-0032-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 03/09/2012] [Indexed: 12/17/2022]
Abstract
The detection of antibodies is useful to diagnose and/or to classify autoimmune diseases as connective tissue diseases and vasculitis. Zenit RA is a fully automated immunoanalyzer. The aim of this study was to compare the predictive and discriminative performance of the Zenit RA anti-cyclic citrullinated peptide (CCP), anti-cardiolipin (aCL) and anti-β 2 glycoprotein 1 (aB2GP1) tests to conventional ELISAs on clinically well-defined groups of patients and to daily evaluate the determination of anti-extractable nuclear antigen (ENA), anti-double stranded DNA (dsDNA), anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3) antibodies in a hospital laboratory. Reagents available on Zenit RA analyzer exhibit good diagnostic performances, regarding sensitivity, specificity, positive and negative predictive values. Global agreements between Zenit RA and conventional tests were from 90 to 98 % (Kappa-values ranging 0.56-0.94): 96 % for anti-CCP, 90-94 % for aCL and aB2GP1, 94 % for anti-dsDNA, 97 % for anti-ENA, 98 % for anti-MPO and 95 % for anti-PR3 antibodies. Zenit RA analyzer is easy to rapidly detect the most common autoantibodies in autoimmune diseases. This system has a potential to provide clinically useful data within a short time. Because of the flexibility of its work modalities, it is well adapted to determine antigenic specificities in daily practice.
Collapse
Affiliation(s)
- P. Ghillani
- Department of Immunology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
- Laboratoire d’Immunochimie, Département d’Immunologie, Groupe Hospitalier Pitié-Salpêtrière, 83 bld de l’Hôpital, 75013 Paris, France
| | - L. Dufat
- Department of Immunology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - S. Himeur
- Department of Immunology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - M. Miyara
- Department of Immunology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Z. Amoura
- Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - L. Musset
- Department of Immunology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Paris, France
| |
Collapse
|
46
|
Miyara M, Diemert MC, Amoura Z, Musset L. Anticorps antiphospholipides en pratique. Rev Med Interne 2012; 33:176-80. [DOI: 10.1016/j.revmed.2011.09.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 09/27/2011] [Indexed: 11/30/2022]
|
47
|
Miyara M, Arnaud L, Dufat L, Ankri A, Mathian A, Haroche J, Boutin-Le Thi Huong D, Ghillani-Dalbin P, Costedoat-Chalumeau N, Piette J, Musset L, Amoura Z. Les titres d’anticorps antiphosphatidylsérine/prothrombine (aPS/PT) sont fortement corrélés aux tests de recherche d’anticoagulants circulants lupiques chez les patients ayant des anticorps antiphospholipides. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
48
|
Miyara M, Chader D, Musset L, Gorochov G, Amoura Z. Détermination des conditions de culture permettant l’expansion de Tregs naïfs exprimant fortement et durablement FOXP3 in vitro à des fins thérapeutiques dans les maladies auto-immunes systémiques. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Bloch-Queyrat C, Drouot L, Charuel J, Yada E, Urien S, Musset L, Boyer O, Benveniste O. Rôle pathogénique des anticorps anti-SRP (signal recognition particle) au cours des myopathies nécrosantes associées. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
50
|
Miyara M, Arnaud L, Dufat L, Ankri A, Mathian A, Haroche J, Boutin-Le Thi Huong D, Ghillani-Dalbin P, Costedoat-Chalumeau N, Piette J, Musset L, Amoura Z. La présence simultanée d’IgG et d’IgM anti-phosphatidylsérine/prothrombine pourrait être associée à l’occurrence de syndromes catastrophiques des antiphospholipides chez les patients porteurs d’anticorps antiphospholipides. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|